|
Market Closed -
Nasdaq
00:30:00 27/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.7540 USD | +1.11% |
|
-7.44% | -33.86% |
| 03:33pm | Top Premarket Gainers | MT |
| 10-12 | Iridex Says Glaucoma Therapy Lowers Eye Pressure, Reduces Medication Use | MT |
| Market Cap | 13.1M 11.71M 10.84M 9.81M 18.36M 1.25B 18.66M 130M 51.58M 652M 49.16M 48.11M 2.06B | P/E 2026 * |
-6.21x | P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 13.1M 11.71M 10.84M 9.81M 18.36M 1.25B 18.66M 130M 51.58M 652M 49.16M 48.11M 2.06B | EV / Sales 2026 * |
0.25x | EV / Sales 2027 * | 0.23x |
| Free-Float |
60.42% | Yield 2026 * |
-
| Yield 2027 * | - |
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| IRIX | Delayed | |
CBOE
| IRIX | Real-time |
Last Transcript: IRIDEX Corporation
| 1 day | +1.11% | ||
| 1 week | -7.44% | ||
| Current month | +19.68% | ||
| 1 month | +20.64% | ||
| 3 months | -15.36% | ||
| 6 months | -28.87% | ||
| Current year | -33.86% |
| 1 week | 0.73 |  | 0.84 |
| 1 month | 0.62 | | 1.02 |
| Current year | 0.61 | | 1.65 |
| 1 year | 0.61 | | 1.65 |
| 3 years | 0.61 | | 3.65 |
| 5 years | 0.61 | | 9.46 |
| 10 years | 0.61 | | 16.39 |
| Manager | Title | Age | Since |
|---|---|---|---|
Patrick Mercer
CEO | Chief Executive Officer | 54 | 01/10/2024 |
Romeo Dizon
DFI | Director of Finance/CFO | 68 | 18/12/2018 |
Philip Taylor
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Scott Shuda
CHM | Chairman | 60 | 24/06/2020 |
Patrick Mercer
BRD | Director/Board Member | 54 | 01/09/2018 |
Beverly A. Huss
BRD | Director/Board Member | 66 | 17/03/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/10/26 | Tax | Chief Executive Officer | -23,917 | 0.1362% | ||
| 16/09/26 | Buy | Chief Financial Officer | 7,900 | 0.0450% | ||
| 14/09/26 | Buy | Chief Financial Officer | 2,354 | 0.0134% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.11% | -7.44% | -31.14% | -74.35% | 13.1M | |
| +1.64% | -0.74% | +19.63% | +58.11% | 249B | |
| +1.07% | +1.72% | +4.47% | +20.93% | 162B | |
| -0.15% | +5.84% | -17.36% | +69.40% | 157B | |
| -0.24% | +2.68% | -54.92% | -8.82% | 66.22B | |
| -1.50% | +2.52% | +8.59% | +63.35% | 52.3B | |
| +1.03% | +2.03% | -14.62% | -11.58% | 52.18B | |
| +1.67% | +4.57% | +19.00% | +32.51% | 51.34B | |
| +1.67% | +1.73% | +18.87% | +70.17% | 48.79B | |
| +0.51% | +4.36% | +26.84% | +88.19% | 44.57B | |
| Average | +0.62% | +1.06% | -2.06% | +30.79% | 88.35B | |
| Weighted average by Cap. | +0.63% | +1.40% | +2.30% | +45.16% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 52.52M 46.96M 43.45M 39.34M 73.63M 5B 74.84M 523M 207M 2.61B 197M 193M 8.28B | 55.98M 50.05M 46.31M 41.93M 78.48M 5.33B 79.76M 557M 220M 2.79B 210M 206M 8.82B |
| Net income | -2.09M -1.87M -1.73M -1.56M -2.92M -198M -2.97M -20.77M -8.21M -104M -7.83M -7.66M -329M | 1K 894.2 827.29 749.05 1.4K 95.14K 1.42K 9.96K 3.94K 49.76K 3.75K 3.67K 158K |
| Net Debt | - | - |
Employees
93
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/10/26 | $0.7540 | +1.11% | 9,389 |
| 23/10/26 | $0.7457 | -2.18% | 19,062 |
| 22/10/26 | $0.7623 | -0.70% | 16,156 |
| 21/10/26 | $0.7677 | +1.68% | 26,355 |
| 20/10/26 | $0.7550 | -1.95% | 37,280 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.7457USD
Average target price
2.750USD
Spread / Average Target
+268.78%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IRIX Stock
Select your edition
All financial news and data tailored to specific country editions
